Trial Profile
A Phase II Study exploring the feasibility of Azacitidine and Lenalidomide use (combination vs sequential treatment) for Higher-Risk Myelodysplastic Syndromes (MDS) (IPSS Risk: High or INT-2)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2020
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms RV-MDS-PI0550REV-AZA
- Sponsors Celgene International SARL
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 08 Dec 2015 Status changed from recruiting to active, no longer recruiting, as per an abstract presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology